ArticleFrontiers in pharmacology2021

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.

Xuezhi Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.